{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T21:03:22Z","timestamp":1785186202475,"version":"3.55.0"},"reference-count":32,"publisher":"American Society of Hematology","issue":"24","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,12]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Recent advances in acute myeloid leukemia (AML) come from studies investigating older adults aged &amp;lt;60 years, those aged \u226575 years, or less fit adults. Uncertainty exists for the management of otherwise healthy adults with AML in their 60s and 70s, which also represents a significant proportion of AML cases. We discuss current considerations in older, fit adults with AML, including determination of fitness, factors beyond fitness that should be assessed, and challenges and innovations to improve patient outcomes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/blood.2024026004","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T21:32:59Z","timestamp":1737754379000},"page":"2840-2846","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["The fit older adult with acute myeloid leukemia: clinical challenges to providing evidence-based frontline treatment"],"prefix":"10.1182","volume":"145","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1165-4766","authenticated-orcid":false,"given":"Sameem","family":"Abedin","sequence":"first","affiliation":[{"name":"1Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7809-0996","authenticated-orcid":false,"given":"Geoffrey L.","family":"Uy","sequence":"additional","affiliation":[{"name":"2Division of Oncology, Washington University School of Medicine, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura C.","family":"Michaelis","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"6","key":"2025061211211185400_bib1","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1182\/blood.2023022611","article-title":"Determining treatment tolerance and fitness for intensive chemotherapy in older adults with AML: a call to action","volume":"143","author":"Bhatt","year":"2024","journal-title":"Blood"},{"issue":"33","key":"2025061211211185400_bib2","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1200\/JCO.2011.35.7525","article-title":"Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment","volume":"29","author":"Walter","year":"2011","journal-title":"J Clin Oncol"},{"issue":"12","key":"2025061211211185400_bib3","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1001\/jamaoncol.2017.2714","article-title":"Development and validation of a novel acute myeloid leukemia-composite model to estimate risks of mortality","volume":"3","author":"Sorror","year":"2017","journal-title":"JAMA Oncol"},{"issue":"21","key":"2025061211211185400_bib4","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1182\/blood-2012-12-471680","article-title":"Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia","volume":"121","author":"Klepin","year":"2013","journal-title":"Blood"},{"issue":"11","key":"2025061211211185400_bib5","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood.2021013671","article-title":"Geriatric assessment predicts nonfatal toxicities and survival for intensively treated older adults with AML","volume":"139","author":"Min","year":"2022","journal-title":"Blood"},{"issue":"5","key":"2025061211211185400_bib6","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/leu.2012.303","article-title":"Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making","volume":"27","author":"Ferrara","year":"2013","journal-title":"Leukemia"},{"issue":"suppl 1","key":"2025061211211185400_bib7","doi-asserted-by":"crossref","first-page":"9057","DOI":"10.1182\/blood-2022-169307","article-title":"Umbrella trial in myeloid malignancies: the Myelomatch national clinical trials network precision medicine initiative [abstract]","volume":"140","author":"Little","year":"2022","journal-title":"Blood"},{"issue":"6","key":"2025061211211185400_bib8","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1038\/s41375-018-0068-2","article-title":"Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of alliance studies","volume":"32","author":"Eisfeld","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"2025061211211185400_bib9","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1182\/asheducation.V2016.1.24.088333","article-title":"Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment?","volume":"2016","author":"Heuser","year":"2016","journal-title":"Hematology"},{"issue":"10388","key":"2025061211211185400_bib10","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Erba","year":"2023","journal-title":"Lancet"},{"issue":"7","key":"2025061211211185400_bib11","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2025061211211185400_bib12","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1182\/blood-2019-127423","article-title":"Management of neutropenia during venetoclax-based combination treatment in patients with newly diagnosed acute myeloid leukemia [abstract]","volume":"134","author":"Pratz","year":"2019","journal-title":"Blood"},{"issue":"4","key":"2025061211211185400_bib13","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/ajh.27246","article-title":"Long-term follow-up of VIALE-A: venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia","volume":"99","author":"Pratz","year":"2024","journal-title":"Am J Hematol"},{"issue":"suppl 1","key":"2025061211211185400_bib14","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1182\/blood-2021-151285","article-title":"Comparative effectiveness of venetoclax combinations vs other therapies among patients with newly diagnosed acute myeloid leukemia: results from the AML Real World Evidence (ARC) initiative [abstract]","volume":"138","author":"Garcia","year":"2021","journal-title":"Blood"},{"issue":"24","key":"2025061211211185400_bib15","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/bloodadvances.2021005538","article-title":"Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia","volume":"5","author":"Cherry","year":"2021","journal-title":"Blood Adv"},{"issue":"13","key":"2025061211211185400_bib16","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1182\/bloodadvances.2022007265","article-title":"Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia","volume":"6","author":"Matthews","year":"2022","journal-title":"Blood Adv"},{"issue":"11","key":"2025061211211185400_bib17","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"2025061211211185400_bib18","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1182\/blood-2022-169509","article-title":"ELN risk stratification is not predictive of outcomes for treatment-na\u00efve patients with acute myeloid leukemia treated with venetoclax and azacitidine [abstract]","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"21","key":"2025061211211185400_bib19","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1182\/blood.2024024944","article-title":"Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine","volume":"144","author":"Dohner","year":"2024","journal-title":"Blood"},{"issue":"26","key":"2025061211211185400_bib20","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1182\/blood.2024026925","article-title":"Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML","volume":"144","author":"Lachowiez","year":"2024","journal-title":"Blood"},{"issue":"2","key":"2025061211211185400_bib21","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41375-024-02143-8","article-title":"Clinical evaluation of complete remission (CR) with partial hematologic recovery (CRh) in acute myeloid leukemia: a report of 7235 patients from seven cohorts","volume":"38","author":"Appelbaum","year":"2024","journal-title":"Leukemia"},{"issue":"12","key":"2025061211211185400_bib22","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1016\/j.bbmt.2011.06.005","article-title":"Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission","volume":"17","author":"Farag","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"2025061211211185400_bib23","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1038\/s41375-019-0477-x","article-title":"Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study","volume":"33","author":"Ustun","year":"2019","journal-title":"Leukemia"},{"issue":"25","key":"2025061211211185400_bib24","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"2025061211211185400_bib25","doi-asserted-by":"crossref","first-page":"e879","DOI":"10.1016\/S2352-3026(23)00273-9","article-title":"10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial","volume":"10","author":"L\u00fcbbert","year":"2023","journal-title":"Lancet Haematol"},{"issue":"8","key":"2025061211211185400_bib26","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/ajh.25162","article-title":"Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience","volume":"93","author":"Ganzel","year":"2018","journal-title":"Am J Hematol"},{"issue":"13","key":"2025061211211185400_bib27","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1200\/JCO.23.01911","article-title":"Azacitidine, venetoclax, and gilteritinib in newly diagnosed and relapsed or refractory FLT3-mutated AML","volume":"42","author":"Short","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4","key":"2025061211211185400_bib28","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1158\/2643-3230.BCD-22-0205","article-title":"A phase Ib\/II study of ivosidenib with venetoclax \u00b1 azacitidine in IDH1-mutated myeloid malignancies","volume":"4","author":"Lachowiez","year":"2023","journal-title":"Cancer Discov"},{"issue":"suppl 1","key":"2025061211211185400_bib29","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2023-182337","article-title":"Early results of the phase I\/II study investigating the all-oral combination of the menin inhibitor revumenib (SNDX-5613) with decitabine\/cedazuridine (ASTX727) and venetoclax in acute myeloid leukemia (SAVE) [abstract]","volume":"142","author":"Issa","year":"2023","journal-title":"Blood"},{"issue":"30","key":"2025061211211185400_bib30","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1200\/JCO.20.00572","article-title":"Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): a phase Ib dose-escalation study of venetoclax combined with modified intensive chemotherapy","volume":"38","author":"Chua","year":"2020","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2025061211211185400_bib31","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1182\/blood-2019-125579","article-title":"APR-246 combined with azacitidine (AZA) in TP53 mutated myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). a phase 2 study by the Groupe Francophone Des My\u00e9lodysplasies (GFM) [abstract]","volume":"134","author":"Cluzeau","year":"2019","journal-title":"Blood"},{"issue":"suppl 1","key":"2025061211211185400_bib32","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1182\/blood-2021-145208","article-title":"A phase 3, randomized, open-label study evaluating the safety and efficacy of magrolimab in combination with azacitidine in previously untreated patients with TP53-mutant acute myeloid leukemia [abstract]","volume":"138","author":"Daver","year":"2021","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/24\/2840\/2379059\/blood_bld-2024-026004-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/145\/24\/2840\/2379059\/blood_bld-2024-026004-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T15:21:22Z","timestamp":1749741682000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/145\/24\/2840\/535274\/The-fit-older-adult-with-acute-myeloid-leukemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,12]]},"references-count":32,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2025,6,12]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2024026004","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6,12]]},"published":{"date-parts":[[2025,6,12]]}}}